Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Open accessThe DOI matches its Crossref record; 141 of the 145 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a growing global concern. These comorbidities include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others, which have a negative impact on health and increase morbidity and mortality. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss. Our aim is to emphasize the active role and main outcomes of GLP-1 agonists in promoting weight loss, as well as in improving hyperglycemia, insulin sensitivity, blood pressure, cardio–metabolic, and renal protection. We highlight the pleiotropic effects of these medications, along with their indications, contraindications, and precautions for both diabetic and non-diabetic patients, based on long-term follow-up studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP‐1 receptor agonists, including liraglutide, semaglutide, and tirzepatide (dual GIP/GLP agonists), have revolutionised the field of obesity pharmacotherapy by facilitating substantial weight loss, achieving an average reduction of 9% with liraglutide, up to 15% with semaglutide, and 18% with tirzepatide [11, 12].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is a critical consideration, as GLP-1RA treatment duration in patients with obesity is highly variable, ranging up to 24 months depending on weight loss goals.18”
From GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“There were no significant differences in hospitalization rates for non-fatal myocardial infarction, non-fatal stroke, and heart failure between the liraglutide and placebo groups [89].”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 21×
“The first approach aimed at prolonging the hal -life of GLP-1 y i h bitin its degradation by DPP-4 through the d vel pment of DPP-4 inhibitors.”
BackgroundInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 2×
“9 kg) resulted in smaller changes [65].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613 · cited 2×
“sclerosis, heart failure [14], and atrial fibrillation [15], while metabolic complications in-”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 3
- Al-Omar M.A. Al-Suwailem A.K. Al-Tamimi A.S. Al-Suhibani M.S. Safety and mechanism of action of orlistat (tetrahydrolipstatin) as the first local antiobesity drug J. Appl. Sci. Res. 2006 2 205 208
- Kanwal S. AlEmadi E.A. Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review Middle East J. Fam. Med. 2021 19 72 83
- Clinical Review Report: Semaglutide (Ozempic): (Novo Nordisk Canada Inc.): Indication: For the Treatment of Adult Patients with Type 2 Diabetes Mellitus to Improve Glycemic Control, in Combination with Metformin (Second-Line Treatment), and in Combination with Metformin and Sulfonylurea (Third-Line Treatment) [Internet] Canadian Agency for Drugs and Technologies in Health Ottawa, ON, Canada 2019 31305971
Cited by
Items 201–294 of 294
Extending Healthspan via GLP-1 Receptor Agonist: Insights and Perspectives
Chakrabarti, S. K., & Chattopadhyay, D. (2026) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2025.00036 · Cited by 1
Experience with Netakimab and a GLP-1 agonist in patients with psoriasis and metabolic syndrome
Kruglova, L. S., Bridan-Rostovskaya, A. S., & Шатохина, Е. А. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-3-28-34 · Cited by 1
Cronenberger, C., Amin, N. B., Le, V., Carvajal‐Gonzalez, S., Ashworth, A. L., Yi, E. C., Schuster, T., ZHANG, Y., Frederich, R. C., Friedman, G. S., et al. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70158 · Cited by 1
What obgyns need to know about GLP-1 receptor agonists
Chauhan, I. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001116 · Cited by 1
Song, K., Zhang, Q., Li, S., Du, Q., Ng, S. K., Chen, Y., Pu, Y., Widjaja, J., Chen, H., & Chen, Y. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00726-3 · Cited by 1
“Among these agents, glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide, have demonstrated substantial efficacy in promoting weight loss and improving metabolic profiles [ 7–9].”
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists
Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1
Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis
Alnaimi, S. J., Alsugeir, D. M., Wei, L., Harvey, K., & Brauer, R. (2026) · Clinical Obesity · doi:10.1111/cob.70092 · Cited by 1
Emara, A., Emara, M., Mansour, A., Elkholy, M., Abbas, O., Abdul‐Hafez, H. A., Azzawi, M. A. D. A., & Shubietah, A. R. M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02218-9 · Cited by 1
A feminist neomaterialist exploration of bariatric surgery in Canada
Bessey, M., & Rice, C. M. (2026) · Body & Society · doi:10.1177/1357034x261480061 · Cited by 1
“Our research extends these conversations by examining the politics of a rapidly changing medical landscape and its implications for fat people, where bariatric surgery and, more recently, pharmaceutical interventions have become increasingly common (Popoviciu et al., 2023).”
Schilddrüsenkarzinom als potenzielles Risiko bei der Behandlung mit GLP-1-RA?
Rogal, K. (2024) · Info Diabetologie · doi:10.1007/s15034-024-4991-1 · Cited by 1
Novas terapias para obesidade: eficácia e segurança dos agonistas de GLP-1
Gonçalves, F. S., & Lima, A. R. L. R. (2025) · Research Society and Development · doi:10.33448/rsd-v14i1.48004 · Cited by 4
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
“Specifically, every 5‑unit increase in BMI above 25 kg/m 2 has been shown to increase overall mortality by 29%, vascular mortality by 41% and diabetes‑related mortality by 21% (6,7).”
MIR192 upregulates GLP-1 receptor and rescues statin-induced impairment of insulin secretion
Kuang, Y., Locatelli, C. A. A., Zhang, Y., Qin, Y., Theusch, E., Munoz-Howell, A., Sanchez, G., Lu, M., Nguyen, M.-A., Yalamanchili, T., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03353-3 · Cited by 1
Pharmacological methods for weight reduction and their connection with the human gut microbiota
Denchev, V. D., & Handjieva‐Darlenska, T. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e114567 · Cited by 1
“…in higher doses when combined with other antidiabetic drugs from the sulfonylurea class; extremely uncommon when used independently) and local inflammatory skin reaction near the site of injection (for the ones applied subcutaneously) (Ryder 2013; Consoli and Formoso 2014; Popoviciu et al. 2023).”
BackgroundInfluentialAlmasi, M. H., Barzin, M., Khalaj, A., Mahdavi, M., Valizadeh, M., & Hosseinpanah, F. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-11240-9 · Cited by 1
Chen, B. S., Tang, I.-K., Lo, J.-Y., Huang, J., Dong, C., Wu, C. H., Yen, F., & Wei, J. C. C. (2025) · Research Square · doi:10.21203/rs.3.rs-7126343/v1 · Cited by 1
Gomes, J. L. D. S., Motta, H. A. P., Macedo, M. L. F. R., Dorneles, J. A., Leal, S. B., Paculdino, L. D. O., Soares, L. A., de Araújo, I. N. B., Campos, B. G., & da Silva, V. H. M. P. (2023) · Research Society and Development · doi:10.33448/rsd-v12i9.43306 · Cited by 3
Hocaoğlu-Emre, F. S. (2023) · International Conference on Recent Academic Studies · doi:10.59287/as-proceedings.114
NEW TREATMENTS FOR OBESITY: DOUBLE AGONIST TWO GIP/ GLP-1 RECEPTORS – TIRZEPATIDE
Pinto, G. M., Gonçalves, M. C., Duarte, P. L. S., Mendes, E. A. B. N., Massariol, L. B., Navarro, M. P. T. B. D. M., Burnier, V. D. L., Rosa, J. D. A. A., Fonseca, L. C., Carbone, M., et al. (2024) · International Journal of Health Science · doi:10.22533/at.ed.1594122423011
Rusminingsih, E., Susanto, H., Afifah, D. N., Wibowo, J., & Anas, Y. (2024) · Jurnal Kebidanan dan Keperawatan Aisyiyah · doi:10.31101/jkk.3553
“GLP-1 has effects on various organ systems, most relevantly causing a decrease in body weight in the long term (Popoviciu et al., 2023).”
BackgroundGlucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
Rabenda, M., Słomczyński, A., Zatyka, P., Pawłowska, A., Opala, D., Osuch, D., & Janik, P. E. (2024) · Quality in Sport · doi:10.12775/qs.2024.20.53995 · Cited by 1
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
Moore, K. T., Gupta, A. S., Shen, J., & Kumar, P. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6136
Retrospective Analysis Comparing the Efficacy of GLP-1 Receptor Agonists Dulaglutide and Semaglutide
Traverse, M., Singh, G., Krecic, C., Abrams, K., Dodson, S., Haykal, S., Barry, S., & Mukka, S. K. (2024) · Guthrie Journal · doi:10.3138/guthrie-2024-0008
Matsumi, Y., Kikuchi, S., Shoji, R., Teraishi, F., & Fujiwara, T. (2024) · Cureus · doi:10.7759/cureus.71401
Erhöhen GLP-1-Rezeptoragonisten das Risiko für Schilddrüsenkarzinome?
Rogal, K. (2024) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-024-0734-7
USO DO SEMAGLUTIDA NO TRATAMENTO DA OBESIDADE: TENDÊNCIAS E PERSPECTIVAS ATUAIS
de Lira, F. A., de Lima, S. D. S. T., Almeida, M. M., Hirashima, M. R. D. S., Goes, C. D. A., de Siqueira, A. L. A. B., Copola, M. L. B. P., Picinin, J. N., Rojas, J. H., Odaka, N. E., et al. (2024) · Revista Contemporânea · doi:10.56083/rcv4n11-160
Yeremian, S., Keshishian, A., & Mardirosian, R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344917
Moving Forward to Disentangle the Role of the Brain in Human Obesity
Hesse, S. (2024) · Brain Sciences · doi:10.3390/brainsci14121245
Li, Y., Hsu, C.-T., Yang, T., & Cheng, K. (2025) · Pharmaceuticals · doi:10.3390/ph18010110
“In clinical trials, GLP-1R agonists have been shown to stabilize and decrease blood glucose levels while also promoting weight loss [10].”
Li, Z., & Nie, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21630-5.00011-3
Tirzepatide as an Emerging Modality for Management of Obstructive Sleep Apnea
Gothi, D., Ish, P., & Malhotra, N. (2025) · Indian Journal of Sleep Medicine · doi:10.5005/jp-journals-10069-0151
A RELAÇÃO ENTRE O USO DE MIMÉTICOS DE GLP-1 E A FERTILIDADE FEMININA EM MULHERES OBESAS
OLIANI, A. L. G., OLIANI, A. G., FIORE, B. R. R. D., SILVA, G. S., ALVES, G. P. W., MEGIOLARO, M. D. R., Alves, M. M. C., & KADRI, S. C. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-230-7.1
Nouveaux médicaments de l’obésité : quelle pertinence ?
Bringer, J. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.008
Multidisciplinary Care in Body Contouring: An Integrative Approach to Enhancing Outcomes
Dinis, J., Otero, S. P., Quirarte, D. M., Owens, W. R., & Winocour, S. J. (2025) · Seminars in Plastic Surgery · doi:10.1055/s-0045-1807724
Translational pharmacology and biomarkers applied to GPCR
Özcelik, D., Andreetta, F., & van der Kam, E. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00036-4
Secondary Natural Products in Foods and Food Systems
Hanley, B. (2025) · Springer eBooks · doi:10.1007/978-3-032-00292-1_1
Mousa, M., Nofal, S., Al‐Ashmawy, G. M., & Khedr, E. G. (2025) · AlSalam International Journal of Pharmacy · doi:10.21608/aijp.2025.414761.1010
“It has been revealed that GLP-1 receptor agonists have been identified to play essential roles in weight loss, which happens mostly due to a decrease in adipose tissue(Popoviciu et al., 2023).”
Chronic kidney disease in metabolic syndrome
Вадимовна, В. С., & Звартау, Н. Э. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6537 · Cited by 5
Vahedi, F., Yalamanchi, M., & Issa, D. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001134
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Andreyeva, E., Graham, M. L., Eldridge, G. D., Folta, S. C., Nelson, M. E., Strogatz, D. S., & Seguin‐Fowler, R. A. (2025) · Obesity · doi:10.1002/oby.70050
“Recently, glucagon-like peptide-1 (GLP-1) agonists have been proven to be effective for obesity control [41].”
Vastrad, B. M., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8076420/v1
The Ozempic Generation: What the Interventional Radiologist Needs to Know About GLP ‐1 Agonists
Wani, S., Findakly, S., Phan, T. D., Lukies, M. W., Goh, G. S., Venn, G., Joseph, T., Koukounaras, J., & Clements, W. (2025) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.70045
“Studies have also shown other benefits from taking these drugs including lowering of all-cause cardiovascular mortality, and improvement in rates of obstructive sleep apnoea [6–8].”
Utility of fluorinated α-amino acids in development of therapeutic peptides
Richardson, P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601105 · Cited by 1
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
“61,63 Slowed gastric emptying and transient nausea induced by GLP-1 analogs may contribute to weight loss, but their role is thought to be minor and short-lived.”
InfluentialAgeeli, M., Flynn, M., Lopes, M. P., İnce, B., Alves, D., Westwood, S. J., Campbell, I. C., & Schmidt, U. H. (2026) · Pilot and Feasibility Studies · doi:10.1186/s40814-025-01748-9 · Cited by 1
GLP-1 receptor agonists and depression in obesity: current evidence
Głaz, D., Deska, Ł., Zysiak, S., Głaz, M., Kamińska, N., Zaguła, J., Sołtys, W., Kosmecki, C., Stronczyński, M., & Wicha, K. (2026) · Archiv Euromedica · doi:10.35630/2026/16/iss.1.005
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Pediatric Obesity
KURAN, Ö., & Cömert, T. K. (2026) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-026-00370-y · Cited by 1
“The anorectic effects of GLP-1 and GLP-1 RAs have been reported to involve direct actions in brain regions that regulate energy balance and appetite as well as indirect mechanisms mediated by gut-to-brain signalling via the vagus nerve [12].”
Effects of Npy1r limbic conditional knock-out on adipose tissue metabolism
Einaudi, G., Oberto, A., Bertocchi, I., Aimaretti, E., Alves, G. F., Porchietto, E., Cifani, C., Bonaventura, M. V. M. D., Collino, M., & Chiazza, F. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110941 · Cited by 1
“Therapeutic peptides, particularly those that mimic the Glucagon-Like Peptide-1, have found great success as weight loss therapies (Popoviciu et al., 2023; Wang et al., 2023).”
A Content Analysis of Web Pages on “Weight-Loss Injections”
Asuman, O. K. U. R. (2026) · Cerasus journal of medicine. · doi:10.70058/cjm.1852434
GLP-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS: CLINICAL IMPLICATIONS BEYOND GLYCEMIC CONTROL
Abella, P. L., FÜRST, I. H., ROZA, L. R. D., Matos, G. P., ZOLET, J. P. V., MARCUZZO, T. C. V., Franceschini, E., Cordova, E. A., SMOLA, V. D. F., SNEL, L. P. F., et al. (2026) · Open Minds International Journal · doi:10.22533/at.ed.5157272624031
Denatonium Benzoate, the Most Bitter Compound, Reduces Weight by Promoting Adipocyte Browning
Niu, Y., Shao, J., Teng, Y., Zhang, C., Xie, X., & Guo, S. (2026) · Metabolites · doi:10.3390/metabo16040242
Yuan, H., Chan, Y., Chen, G., Xu, L., Zhang, C., Tang, G., Feng, Y., & Wang, N. (2026) · Food Frontiers · doi:10.1002/fft2.70275
Allan, V., Kulkarni, S., Wang, Z., Tomlinson, J. W., Hippisley‐Cox, J., Collins, G. S., Clift, A. K., Dodwell, D. J., & Lord, S. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2026.100700
“…in understanding this complex relationship will be the increasing availability and exposure of patients to GLP-1 and dual GIP/GLP-1 receptor agonists and other treatments in development for use in diabetes and weight loss, 40 and arguably, longitudinal BMI measures will become even more important.”
Wojcik-Sosnowska, E., Tabeau, A., Pawlik, A., Węglarz, B., & Czupryniak, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093882
“Differences in half-life, molecular size, and receptor affinity may partly explain variability in metabolic and safety outcomes, yet the overall class trend supports a shared incretin-mimetic mechanism [22,23].”
InfluentialGenetic variability in the leptin-melanocortin pathway and its role in weight loss
Monteiro, M. P., Guimarães, M., Monteiro, M. P., Pereira, S. S., & Azevedo, L. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102377
“Liraglutide has been demonstrated to be effective in achieving a body weight reduction of 5 — 10% and maintaining WL [31].”
Digital Augmentation of Glucagon-Like Peptide-1 for Obesity Management: Retrospective Study
Davey, B., Dabash, O., Khanna, R., Cornell, P. Y., & Huckvale, K. (2026) · Journal of Medical Internet Research · doi:10.2196/100728
Borkowski, K., Leja, W., Błaszczak, M., Latalska, K., Szczupaj, M., Januszczak, R., Pastuszak, A., Rudnicki, J., Zjawiony, J., & Zulfiqar, Z. (2026) · Quality in Sport · doi:10.12775/qs.2026.55.71099
Jain, A., Shrivastav, Y., Manocha, N., Baraskar, G., Bisht, R., Bhawsar, D., & Retrekar, N. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.30s.55
“In particular, the impact of GLP-1 RAs on glucose homeostasis and body weight in diabetic and normal subjects will also be brought into the limelight with recognition of their pleiotropic actions, not limited to glucose regulation but also to cardiometabolic well-being and renal safeguards [16].”
Cahill, T., Nalesso, V., Clarke, P., de Lagrán, M. M., Strydom, A., Li, C., Potier, M., Beckers, J., Langohr, K., Lió, P., et al. (2026) · Nutrients · doi:10.3390/nu18111692
Almuharraq, L. M. E., Alshanqeti, H. M. A. M., Almutairi, A. M., Jabour, H. M. M., Al-Falih, A. W. R., Al-Anzi, L. N. Z., Wadani, H. M. A., Al-Ghamdi, S. I. A., Al-Ghamdi, F. S. B., Mubarki, E. G., et al. (2024) · Saudi Journal of Medicine and Public Health · doi:10.64483/202412713
Jared, M. C., Koehler, B., & Cohen, S. S. (2026) · International Journal of Qualitative Studies on Health and Well-Being · doi:10.1080/17482631.2026.2673595
“In addition, more evidence is needed on long-term sequelae and effectiveness of these medications for women (Perdomo et al., 2023; Popoviciu et al., 2023).”
Carr, D. J., Kelley, E., Sekhon, M., Kawasaki, M., McElroy-Yaggy, K., Skinner, R. C., Taylor, P. D., David, A. L., Stener‐Victorin, E., & Jetton, T. L. (2026) · Pregnancy · doi:10.1002/pmf2.70312
Yu, C., Ye, X., Zhao, H., 钱素婷, Xie, F., & Liu, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1837504
Kibirige, D., Niwaha, A. J., Katte, J.-C. N., & Lumu, W. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01881-5
Ferreira, J. G., Veras, G. R. M., Souza, A. L. C. D., Araújo, A. A., Duarte, B. Z. E. S., Monteiro, H. B., Sousa, T. A., & dos Santos, K. N. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i6.8139
Coulter, A. A., Greenway, F. L., Ramanathan, G., Hubbard, J. R., & Rebello, C. J. (2026) · Obesity Reviews · doi:10.1111/obr.70173
Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India
Saxena, A., & Prakash, A. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1507
Colditz, G. A., Anandarajah, A., Dart, H., & Stoll, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00077-9
陈, 琳. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662455
Mularczyk, P., Polek, N., Sikorska, M., Łysoniewski, W., Marcysiak, A., Mruzek, T., Kiełbasiewicz, M., & Zawadzka, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5668
“…body-weight control, metabolic profile, and cardiovascular risk, and to increase ovulation rates, menstrual regularity, and the proportion of spontaneous and IVF-mediated pregnancies in obese women with PCOS (K. Elkind-Hirsch et al., 2022; Krzysztof Bednarz et al., 2022; M. Popoviciu et al., 2023).”
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Oldenburg, L. I. K., Haugaard, S. P., Karlsson, T., Kegel, V., Parwez, M., Wiingaard, C., & Flint, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71096
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and amylin receptor (AMYR) agonists offer significant beneficial effects in obesity and T2D, including substantial weight loss, improving glucose control, and reducing CV disease, heart failure and CKD [9–15].”
Bitar, E. R., Besir, K., Cummins, K. C., Sears, O., Moheb, M. E., McKee, K., Ruff, S. M., van der Windt, D. J., & Tsung, A. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102497
Cardoso, B. S. A., Lauande, C. C. S., Rodrigues, M. P. C., & Silva, S. E. C. (2026) · DELOS Desarrollo Local Sostenible · doi:10.55905/rdelosv19.n82-035
Epigenomic Perspective of Obesity in the Context of Aging and Longevity
Kumar, A., & Konar, A. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_4
del Carmen, G. A., Patel, D., Vu, N. H., Tran, A., & Zaman, J. A. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13149-x
Belančić, A., Majanović, S. K., Skroče, K., Ciudin, A., & Borovac, J. A. (2026) · Medicina · doi:10.3390/medicina62081446
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP incretin therapies were initially developed for T2DM but have emerged as effective therapies for obesity management [21].”
Piotrowska, G., Gaczoł, A. A., Kopcińska, P., Mortka, M., Bednarz, H. M., Kawa, M., Idzik, K., Grzybowska, D., Urbaś, A., Lechowska, Z., et al. (2026) · Quality in Sport · doi:10.12775/qs.2026.65.73982
Sundell, I., Wettermark, B., Sundström, A., Martinell, M., Ericsson, B., Lindahl, U., Rubaiy, H. N., & Ekbäck, M. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03488-y
“During the last decade, GLP-1 RAs have been approved for obesity treatment since they have been shown to be effective for promoting weight loss in clinical trials [10, 11].”
Department of Metabolic and Bariatric Surgery in the Era of Social Media
Yang, J., Li, X., Tang, Q., Wu, X., Chen, X., & Li, C. (2026) · Journal of Surgery · doi:10.11648/j.js.20261404.11
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
Monteiro, M. P., Frutuoso, J. F., Pereira, S. S., Guimarães, M., & Monteiro, M. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870008
GLP-1 Receptor Agonists: The Next Multifunctional Class of Drugs
MARBADE, S. (2026) · International Journal of Medical and Health Sciences · doi:10.64823/ijmhs.2601007
“In obese patients, GLP-1 secretion is impaired [8].”
Anaphylaxis to tirzepatide confirmed by positive skin prick testing
Steele, C., & Crisp, H. C. (2026) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2026.09.727
Ji, L., Yang, G., HUANG, Y., Ding, H., Xie, D., Jiang, X., Yuan, X., Cao, Z., Chan, 邹. Z., Zhang, H., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71193
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
From Menarche to Menopause: Why Reproductive History Matters for Cardiovascular Risk Assessment
Adebowale, O. N., & Zakaria, S. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.054211
Snytte, J., Hazan, B., Weissman, A., & MAYROVITZ, H. N. (2026) · Cureus · doi:10.7759/cureus.117072 · Cited by 1
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated substantial benefits in weight reduction and glycemic control and are increasingly prescribed for obesity and type 2 diabetes [6].”
Rapp, H., Marr, D., Modany, A., Bryk, A., CHRISTIAN, N., & Good, C. B. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1167
do Amaral, M. C. M., Pereira, R. M. M., Grassi, I. A., de Holanda, L. T., Grassi, V. M. T., & Grassi, L. T. (2026) · Revista Tópicos · doi:10.70773/revistatopicos/790567364
A Unified Theory of AddictionPreprint
Pretlow, R. A. (2026) · Qeios · doi:10.32388/wsgeq1.6
Jurica, J., Miertová, Z., Péč, M. J., Focko, B., Miert, A., Tudík, P., Nagy, N., Ságová, I., Péčová, M., Bolek, T., et al. (2026) · Obesity Facts · doi:10.1159/ofa/adzag002
“GLP-1RAs have several effects on various organ systems, combining central and peripheral actions that promote satiety, decrease hunger, decrease appetite, and ultimately lead to reduced food intake [7].”
Miethe, S., Potaczek, D. P., Pauck, K., Berlin, A., Alhamwe, B. A., Hagner, S., Nist, A., von Strandmann, E. P., Stiewe, T., Klemm, P., et al. (2026) · Allergy · doi:10.1111/all.70492
Synthesis, Secretion, and Transport of Peptide Hormones
Malandrino, N., & Smith, R. J. (2026) · Endocrinology · doi:10.1007/978-3-319-27318-1_3-3
Metadata
- Authors
- Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S.
- Affiliations
- University of Oradea (RO)
- University of Kaiserslautern (DE)
- Zagazig University (EG)
- Corresponding author
- Cavalu, Simona
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-21
- Volume
- 24
- Issue
- 13
- Pages
- 10449
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10341852
- OpenAlex
- W4381618228
- Semantic Scholar
- f13196d495574d64dbe2e547bd587bb48816b847
- Cited by
- 280
- References
- 145
- Citations by year
- 2026: 70 · 2025: 131 · 2024: 67 · 2023: 12
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- University of Oradea
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, weight loss, type 2 diabetes, hyperglycemia, insulin sensitivity, blood pressure, cardioprotection, renal protection, obesity-related comorbidities, long-term safety, non-diabetic patients
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Peptides, Weight Loss, Randomized Controlled Trials as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.